(Reuters) – The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc (NASDAQ:)’s Alzheimer’s drug, Aduhelm, that was recently approved by the country’s health regulator.
The Centers for Medicare & Medicaid Services expects to give a proposed decision within 6 months and a final decision within 9 months. (https://go.cms.gov/3hzMa6H)
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Need Your Help Today. Your $1 can change life.